The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results.
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss.
A device combining the "palpate & roll technique to vacuum massage, innovation dedicated to efficiency.
...ople, you must understand the patients you care fo...ng population, your patients may need assistance i...nch low height, the Ritter 222 Barrier-Free Exam T...e the elderly, expectant mothers or patients with ...
Medicine Products:(Date:5/12/2008)... to have committed patent and ...2 /PRNewswire-FirstCall/ -- Mannatech,Incorporate...r of dietary,supplements and skin care solutions, ...orthern District of Texas found that Glycoproducts...Mannatech,s patent and,trademark relating to Ambro...
(Date:5/12/2008)...Assists Removal of 975 Cardiac ...12 /PRNewswire-FirstCall/ -- Spectranetics,Corpora...reviewed study,demonstrates Spectranetics, excimer...al of pacing and defibrillator leads. The study, "...e with Transvenous Lead,Extraction: Outcomes and C...
(Date:5/12/2008)...g been known that embryonic stem cells have the ab...cells, the exact mechanism as to how this occurs h...ers at the Hebrew University of Jerusalem and else... process, resolving a long-standing question as to...through selective activation or selective repressi...
(Date:5/12/2008)...tCall/ -- ULURU Inc. (Amex: ULU ),today reported ...h 31,2008., For the quarter ended March 31, 2008... was $1,815,000, or $0.03 per share, compared to a... corresponding period in 2007.,The first quarter 2...$497,000, which included stock option expense, amo...
Breaking Medicine News(10 mins):Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 2Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 3Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 2Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 3Health News:How embryonic stem cells develop into tissue-specific cells demonstrated 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6...d yesterday that a hospitalised woman was tested p...deaths due to bird flu//, the number being the hig...rom the beginning of this year. "A 67-year-old wo...ung had contact with fowl," the official from the ...
...) is likely to take over Johnsonville's Eating Dis...r-end. There are only 2 specialist// inpatient uni... Christchurch. Insufficient financial support by ...gers to the patients and staff for the termination...
... impulse control disorders as a result of treatmen...have appetite changes, according// to a study publ... the scientific journal of the American Academy of...tification of patients at risk for developing this...
...s at Harvard University has borne 'fruit' proving ...your diet could actually curb// gall stone formati... Chung-Jyi Tsai which spanned over a substantial p...ch scrutinized the dietary patterns and incidence ...
Other Medicine News:Health News:Appetite Changes, Depression Signal Impulse Control Disorders in Parkinson 2Health News:Call In Fruits And Vegetables To Avoid Gall Stones 2(Date:5/8/2008)...tion May Provide New Option for Clinicians Concern...g an Oral NSAID, TAMPA, Fla., May 8 /PRNewswire-F...g global specialty pharmaceutical company, announc...k at the American Pain Society annual,meeting demo...armacokinetic,profile of Alpharma Pharmaceuticals,...
(Date:5/7/2008)...Study to Evaluate Efficacy and Safety in Treating ...ness, LEVERKUSEN, Germany, MONTVILLE, New Jersey ...ll/ -- Bayer HealthCare AG and Regeneron,Pharmaceu... the first patient,has been dosed in the VIEW 2 tr...ent program evaluating VEGF Trap-Eye for the treat...
(Date:5/7/2008)...May 7 /- Arena Pharmaceutic...isho Pharmaceutical Co., Ltd.,initiated a Phase 1 ...cused,partnership with Arena to develop compounds ... is a novel oral compound intended for the treatme...y happy to see our long-standing partner, Taisho,...
(Date:5/7/2008)... shows how sounds are amplified in the inner ear, ...result from genetic mutation or,overdose of drugs,...-- St. Jude Children,s,Research Hospital investiga...fication mechanism in the cochlea of the ear is cr...mmals. The findings will enable better,understandi...
Breaking Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 2Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 3Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 4Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 5Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 6Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3St. Jude Finds 'Dancing' Hair Cells Are Key to Humans' Acute Hearing 2St. Jude Finds 'Dancing' Hair Cells Are Key to Humans' Acute Hearing 3Pelosi Statement on House Vote to Extend Family and Medical Leave for Military Families 2164 1Illinois AARP Presses for Expansion of Childrens Health Insurance Program 28SCHIP 29 2161 1Illinois AARP Presses for Expansion of Childrens Health Insurance Program 28SCHIP 29 2161 2Mice teeth explain the troubles with human wisdom teeth 884 1Mice teeth explain the troubles with human wisdom teeth 884 2Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano 882 1Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano 882 2...ILLE, Md., May 21, 2007-The U.S. Food and Drug Adm...ssue related to Avandia,(rosiglitazone), a drug ap...controlled clinical trials have shown that there i...f heart attack and,heart-related deaths in patient...ublished data from long-term clinical trials of,Av...
...IDGE, Mass.--(BUSINESS WIRE)--May 16, 2007 - Glouc...iopharmaceutical,company, announced today that the...ed Fast Track designation for its novel histone,de...py of,previously treated peripheral T-cell lymphom...t it has reached an agreement with the,FDA under t...
Other Medicine Technology:FDA Issues Safety Alert on Avandia 2FDA Issues Safety Alert on Avandia 3Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 2Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 3